Citadel Advisors
ALXO icon

Citadel Advisors’s ALX Oncology ALXO Stock Holding History

Citadel Advisors’s Portfolio ALXO Stock Details ALXO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-56,732
Closed -$108K – 12900
2025
Q4 		$64.1K Buy
+56,732
New +$85.9K ﹤0.01% 11912
2025
Q2 		– Sell
-2,209
Closed -$1.11K – 12384
2025
Q1 		$1.38K Sell
2,209
-34,886
-94% -$41.9K ﹤0.01% 14137
2024
Q4 		$61.9K Buy
+37,095
New +$57K ﹤0.01% 12145
2024
Q3 		– Sell
-68,511
Closed -$255K – 14167
2024
Q2 		$413K Sell
68,511
-1,166,704
-94% -$14.3M ﹤0.01% 8447
2024
Q1 		$13.8M Buy
1,235,215
+2,108
+0.2% +$29.6K ﹤0.01% 2509
2023
Q4 		$18.4M Buy
1,233,107
+807,890
+190% +$7.66M ﹤0.01% 2106
2023
Q3 		$2.04M Buy
425,217
+222,934
+110% +$1.21M ﹤0.01% 5159
2023
Q2 		$1.52M Sell
202,283
-40,599
-17% -$266K ﹤0.01% 5658
2023
Q1 		$1.1M Buy
242,882
+101,533
+72% +$769K ﹤0.01% 6565
2022
Q4 		$1.59M Sell
141,349
-97,037
-41% -$1.09M ﹤0.01% 5912
2022
Q3 		$2.28M Buy
238,386
+160,131
+205% +$1.87M ﹤0.01% 5335
2022
Q2 		$633K Sell
78,255
-55,775
-42% -$607K ﹤0.01% 8118
2022
Q1 		$2.27M Buy
134,030
+45,456
+51% +$776K ﹤0.01% 5811
2021
Q4 		$1.9M Sell
88,574
-5,145
-5% -$222K ﹤0.01% 6359
2021
Q3 		$6.92M Buy
93,719
+71,183
+316% +$4.74M ﹤0.01% 3700
2021
Q2 		$1.23M Sell
22,536
-36,677
-62% -$2.19M ﹤0.01% 7782
2021
Q1 		$4.37M Sell
59,213
-224,043
-79% -$17.6M ﹤0.01% 4570
2020
Q4 		$24.4M Buy
+283,256
New +$17M 0.01% 1603

Other funds holding ALXO

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return

Citadel Advisors's ALXO Position: Q1 2026 in Review

Citadel Advisors sold out of ALX Oncology (ALXO) in Q1 2026, closing a stake of 56,732 shares — an estimated $108K sold.

Citadel Advisors first reported a position in ALXO in Q4 2020 and held it in 18 quarters. The position peaked at $24.4M in Q4 2020. 69 funds tracked by Wall St. Rank hold ALXO as of Q1 2026.

  • Citadel Advisors reported no remaining ALX Oncology position as of Q1 2026 after selling out during the quarter.
  • Citadel Advisors sold 56,732 ALX Oncology shares in Q1 2026, an estimated $108K.
  • Citadel Advisors first reported a position in ALX Oncology in Q4 2020 and held it in 18 quarters.
  • Citadel Advisors's ALX Oncology position peaked at $24.4M in Q4 2020.
  • 69 funds tracked by Wall St. Rank held ALX Oncology as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.